Impax Laboratories (NASDAQ: IPXL) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Insider and Institutional Ownership
90.5% of Impax Laboratories shares are owned by institutional investors. Comparatively, 64.6% of Corcept Therapeutics shares are owned by institutional investors. 3.2% of Impax Laboratories shares are owned by company insiders. Comparatively, 19.2% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent ratings and target prices for Impax Laboratories and Corcept Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Impax Laboratories presently has a consensus target price of $20.29, suggesting a potential downside of 0.56%. Corcept Therapeutics has a consensus target price of $23.33, suggesting a potential upside of 5.15%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Impax Laboratories.
Earnings & Valuation
This table compares Impax Laboratories and Corcept Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Impax Laboratories||$824.43 million||1.83||-$472.03 million||($6.25)||-3.26|
|Corcept Therapeutics||$81.32 million||31.14||$8.14 million||$0.29||76.52|
Corcept Therapeutics has lower revenue, but higher earnings than Impax Laboratories. Impax Laboratories is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Impax Laboratories and Corcept Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Impax Laboratories has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.
Corcept Therapeutics beats Impax Laboratories on 11 of the 14 factors compared between the two stocks.
About Impax Laboratories
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation’s Abraxane) to treat patients with solid-tumor cancers.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.